|
業務類別
|
Biotechnology |
|
業務概覽
|
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options. The Companies current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Companies commercial development program for ZUNVEYL is focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations. |
| 公司地址
| 1200 - 750 West Pender Street, Vancouver, BC, CAN, V6C 2T8 |
| 電話號碼
| +1 858 344-4375 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.alphacognition.com |
| 員工數量
| 71 |
| Mr. Kenneth A. Cawkell, L.L.B. |
Corporate Secretary and Director |
-- |
30/04/2026 |
| Mr. Michael McFadden |
Chief Executive Officer and Director |
美元 625.00K |
30/04/2026 |
| Ms. Lauren D'Angelo |
Chief Commercial Officer and Chief Operating Officer |
美元 500.00K |
30/04/2026 |
| Mr. Henry Du |
Vice President, Finance and Accounting, Interim Chief Financial Officer and Principal Accounting Officer |
美元 285.00K |
30/04/2026 |
|
|
| Mr. Kenneth A. Cawkell, L.L.B. |
Corporate Secretary and Director |
30/04/2026 |
| Mr. Michael McFadden |
Chief Executive Officer and Director |
30/04/2026 |
| Mr. Phillip Mertz |
Independent Director |
30/04/2026 |
| Mr. Rajeev Bakshi |
Independent Director |
30/04/2026 |
| Ms. Bethany L. Sensenig |
Director |
20/04/2026 |
| Dr. Robert Wills, PhD |
Independent Director |
30/04/2026 |
|
|
|
|
